Abstract: Disclosed is a chromatographic process complex for the refining of krill oil extract including desalting, removal of impurities such as trimethylamine oxide (TMAO), and the production of krill oil products including desalted krill oil extract, polar lipid products having polar lipid contents greater than 50 wt-% on a dry or solvent free basis, neutral lipid streams for biodiesel production and astaxanthin. The refinery includes a continuous desalting zone, a fixed bed polar lipid extraction zone to adsorb neutral lipids and astaxanthin to provide a polar lipid extract stream comprising solvent and polar lipids and being essentially free of neutral lipids and astaxanthin, and an astaxanthin separation zone to recover essentially pure astaxanthin and provide a neutral lipid stream. The enriched products of the krill oil refinery are essentially free of TMAO and salt and provide products which can be used as dietary supplements and as medicinal additives.
Type:
Grant
Filed:
February 11, 2015
Date of Patent:
January 31, 2017
Assignee:
OROCHEM Technologies, Inc.
Inventors:
Anil R. Oroskar, Asha A. Oroskar, Alexander B. Smetana, Slobodan Milasinovic, Xuejun Zang
Abstract: With respect to reduced coenzyme Q10, there has been no report about the presence of crystal polymorphism, and it has been considered that a conventionally obtained crystal form is only one form. The present invention relates to a reduced coenzyme Q10 crystal having an endothermic peak indicating melting at 54±2° C. during temperature rise at a rate of 5° C./min by differential scanning calorimetry (DSC), and/or to a reduced coenzyme Q10 crystal showing characteristic peaks at diffraction angles (2?±0.2°) of 11.5°, 18.2°, 19.3°, 22.3°, 23.0° and 33.3° by powder X-ray (Cu—K?) diffraction. The crystal form is a novel reduced coenzyme Q10 crystal which has a higher melting point and a lower solubility in a solvent, and is more excellent in stability than the conventionally known reduced coenzyme Q10 crystal.
Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
Type:
Grant
Filed:
November 20, 2014
Date of Patent:
January 24, 2017
Assignee:
NOVARTIS AG
Inventors:
Heinrich Rueger, Jutta Blank, Vincent Bordas, Simona Cotesta, Guido Bold, Vito Guagnano, Andrea Vaupel
Abstract: Provided is a method for industrially producing a conjugated Z-alken-yn-yl acetate such as Z-13-hexadecen-11-yn-yl acetate which is a sex pheromone component of a pine processionary moth, and an intermediate for the conjugated Z-alken-yn-yl acetate under mild conditions at a high yield. More specifically, provided is a method for producing a conjugated Z-alken-yn-yl acetate (5) comprising the steps of: reacting an ?-halo-2-alkynal (1) with an alkylidene triphenylphosphorane (3) through a Wittig reaction to obtain a conjugated Z-alken-yn-yl halide (4), and acetoxylating the conjugated Z-alken-yn-yl halide (4) into a conjugated Z-alken-yn-yl acetate (5).
Abstract: The present invention relates to a method for removing impurities from nitrated crude products obtained during the nitration of nitratable aromatic compounds, after removal of the final nitrating acid, by treatment with a washing medium, and also to a plant or apparatus suitable for implementing this method. Further provided by the invention is a production plant for the nitration of nitratable aromatic compounds with subsequent purification of the nitrated products.
Type:
Grant
Filed:
February 26, 2015
Date of Patent:
January 10, 2017
Assignee:
Josef Meissner GmbH & Co. KG
Inventors:
Jürgen Pöhlmann, Heinrich Hermann, Mirko Händel, Jürgen Gebauer
Abstract: A medical composition for reducing the rate of new-onset diabetes caused by administration of a statin or for inhibiting an increase in blood glucose level by administration of a statin, the composition containing at least one ingredient selected from the group consisting of icosapentaenoic acid and pharmaceutically acceptable salts or esters thereof as an inactive ingredient.
Abstract: Disclosed is a group of azo quencher compositions useful as fluorescence quenchers having the general structure of formula 1, methods of making or using the compositions, and kits comprising the composition.
Type:
Grant
Filed:
January 9, 2013
Date of Patent:
January 10, 2017
Assignee:
Integrated DNA Technologies, Inc.
Inventors:
Andrei Laikhter, Mark Aaron Behlke, Joseph Walder, Kevin William Roberts, Yawfui Yong
Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
Type:
Grant
Filed:
November 13, 2013
Date of Patent:
January 3, 2017
Assignee:
Asana BioSciences, LLC
Inventors:
Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
Abstract: Screening assays and methods of using same for screening to identify modulator agents or compounds that target endoplasmic reticulum stress related signaling pathways to induce apoptosis are described herein. Pharmaceutical compositions comprising modulator agents or compounds identified by screening assays described herein are also encompassed. Methods for treating a myeloproliferative disorder characterized by monoclonal plasma cell proliferation in a subject using the aforementioned modulator agents or compounds are also envisioned. Modulator agents or compounds thereof for use in treating a myeloproliferative disorder in a subject and use of modulator agents or compounds thereof in the preparation of medicaments for the treatment of a myeloproliferative disorder are also encompassed herein. Exemplary myeloproliferative disorders include: monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM).
Type:
Grant
Filed:
February 25, 2014
Date of Patent:
December 27, 2016
Assignee:
New York University
Inventors:
Seth J. Orlow, Amitabha Mazumder, Nicole Doudican
Abstract: A system for, and method of, recovering salt from fluid stream in a recycle loop of a flash separator has a desanding hydrocyclone located in the hot recycle loop of the flash separator; a first solids fluidization device located at the bottom end of the flash separator's brine column; a second desanding hydrocyclone arranged to receive a salt slurry stream created by the first solids fluidization device; and an accumulator located downstream of the second desanding hydrocyclone and having a second solids fluidization device located at its bottom end. Each solids fluidization device causes a motive fluid to exit the device in a swirling motion to fluidize the salt components contained in the resident fluid. The overflow from the second desanding hydrocyclone is the motive fluid for the brine column and a produced water, condensate water, or seawater stream is the motive fluid for the accumulator.
Abstract: The synthesis of a series of Polyethylene glycol conjugates (esters and carbonates) of PEA and its analogous acylethanolamides, have higher water solubility and good hydrophilic/lipophilic balance, resulting in (i) improved accumulation in tissues (particularly skin and mucosae), (ii) prolonged release, and (iii) increased bioavailability. Improvement of PEA and analogous acylethanolamides levels in the tissues—particularly in the skin and mucosae—and their prolonged release is due to the improved bioavailability of related conjugates. Conjugates are able to extend the time frame in which PEA and analogous acylethanolamides exert their pharmacological effects.
Type:
Grant
Filed:
December 11, 2013
Date of Patent:
December 20, 2016
Assignee:
EPITECH GROUP S.r.l.
Inventors:
Antonio Calignano, Giuseppe D'Agostino, Sonia Laneri, Rosaria Meli, Carmine Ostacolo, Roberto Russo, Antonia Sacchi, Diana Tronino, Francesco Della Valle, Maria Federica Della Valle, Gabriele Marcolongo
Abstract: A tetrazolinone compound represented by formula (1): Wherein R1, R2, R3, and R11 each represents a halogen atom, a C1-C6 alkyl group, etc.; R4 and R5 each represents a hydrogen atom, a halogen atom, a C1-C3 alkyl group, etc.; R6 represents a C1-C3 alkyl group optionally having one or more halogen atoms, etc.; R7, R8, and R9 each represents a hydrogen atom, a halogen atom, etc.; R10 represents a C1-C3 alkyl group, etc.; and R12 represents a phenyl group optionally having one or more atoms or groups selected from Group P3, a phenoxy group optionally having one or more atoms or groups Group P3, etc., has excellent control activity against pests.
Abstract: The present invention pertains to a process for the purification of a substantially water-free liquid feed comprising monochloroacetic acid, dichloroacetic acid, optionally acid chlorides, optionally anhydrides, and optionally acetic acid, which comprises the steps of (a) adding water to the liquid feed so that a liquid feed is obtained comprising between 0.01 and 5% by weight of water, based on the total weight of the liquid feed, and (b) subsequently subjecting the liquid feed obtained in step (a) to a catalytic hydrodechlorination step by contacting it with a source of hydrogen to convert the dichloroacetic acid into monochloroacetic acid in the presence of a solid heterogeneous hydrogenation catalyst comprising one or more metals of Group VIII of the Periodic Table of the Elements deposited on a carrier.
Type:
Grant
Filed:
October 17, 2012
Date of Patent:
November 29, 2016
Assignee:
Akzo Nobel Chemicals International B.V.
Inventors:
Melle Rinze Nieuwhof, Cornelis Kooijman, Willem Koelewijn, Hendrik Jan Vos, Lars Magnus Tollin, Henricus Johannes Marinus Petrus Van Hal
Abstract: Methods and systems for on-site generation of peracid chemistry, namely peroxycarboxylic acids and peroxycarboxylic acid forming compositions, are disclosed. In particular, an adjustable biocide formulator or generator system is designed for on-site generation of peroxycarboxylic acids and peroxycarboxylic acid forming compositions from sugar esters. Methods of using the in situ generated peroxycarboxylic acids and peroxycarboxylic acid forming compositions are also disclosed.
Type:
Grant
Filed:
October 8, 2015
Date of Patent:
November 29, 2016
Assignee:
Ecolab USA Inc.
Inventors:
Paul R. Kraus, Richard J. Mehus, Katherine M. Sanville, Thomas C. Rustad
Abstract: The present invention provides a control agent for a plant pest and/or a plant disease, the control agent being environmentally friendly and having a high control effect. The control agent is a control agent for a plant pest and/or a plant disease, containing a polyglycerin fatty acid ester as an active ingredient. The polyglycerin fatty acid ester is an ester of at least one fatty acid selected from fatty acids having 8 to 10 carbon atoms, and at least one polyglycerin obtained by polymerizing 3 to 10 glycerins.
Abstract: The process of the present invention pertains to a process wherein a liquid feed comprising monochloroacetic acid, dichloroacetic acid, and optionally acetic acid and/or trichloroacetic acid is subjected to a catalytic hydrodechlorination step by contacting it with a source of hydrogen in the presence of a solid heterogeneous hydrogenation catalyst situated in a fixed catalyst bed, wherein the liquid feed is fed to the top of avertical tubular reactor at a superficial mass velocity of between and 10 kg/s per square meter of the horizontal cross-section of the vertical tubular reactor and a rate of between 250 and 3,000 kg/hr per m of said catalyst bed, wherein the source of hydrogen is fed to the top or bottom of the vertical tubular reactor at a rate of between 0.025 to 0.
Type:
Grant
Filed:
October 17, 2012
Date of Patent:
November 29, 2016
Assignee:
Akzo Nobel Chemicals International B.V.
Inventors:
Melle Rinze Nieuwhof, Cornelis Kooijman, Hendrik Jan Vos, Lars Magnus Tollin, Jacobus Van Den Berg, Henricus Johannes Marinus Petrus Van Hal
Abstract: Methods for catalytically dehydrating hydroxypropionic acid, hydroxypropionic acid derivatives, or mixtures thereof to acrylic acid, acrylic acid derivatives, or mixtures thereof with high yield and selectivity and without significant conversion to undesired side products, such as, acetaldehyde, propionic acid, and acetic acid, are provided. The catalysts are mixed monophosphates.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
November 29, 2016
Assignee:
The Procter & Gamble Company
Inventors:
Juan Esteban Velasquez, Janette Villalobos Lingoes, Dimitris Ioannis Collias, Jane Ellen Godlewski
Abstract: Provided herein are compounds, conjugates and methods for making lipid-chemically self-assembled nanorings (Lipid-CSANs) and using them to treat diseases and modify cell surfaces.
Abstract: The invention provides methods for attaching drugs, dyes or radiolabels to bis-MTX. This method can be used to prepare bis-MTX analogs that can be used to deliver agents, such as nanoparticles, drugs, dyes or radiolabels, to cells.
Type:
Grant
Filed:
January 18, 2013
Date of Patent:
November 8, 2016
Assignee:
TYCHON BIOSCIENCE, LLC
Inventors:
Carston R. Wagner, Jae Chul Lee, Sidath C. Kumarapperuma
Abstract: Methods are provided which include converting oripavine to other opiates, including converting oripavine to naltrexone, buprenorphine, 14-hydroxymorphinone and/or converting 14-hydroxymorphinone to oxymorphone. Purification and salt formation are optionally included.